News IceCure Medical Ltd

Equities

ICCM

IL0011224156

Market Closed - Nasdaq Other stock markets 01:28:52 29/05/2024 am IST			5-day change	1st Jan Change
1.04 ^USD	+0.97%		-4.59%	-2.80%

28/05	Transcript : IceCure Medical Ltd, Q1 2024 Earnings Call, May 28, 2024
28/05	Earnings Flash (ICCM) ICECURE MEDICAL Posts Q1 Revenue $743,000, vs. Street Est of $880,000	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Transcript : IceCure Medical Ltd, Q1 2024 Earnings Call, May 28, 2024	28/05
Earnings Flash (ICCM) ICECURE MEDICAL Posts Q1 Revenue $743,000, vs. Street Est of $880,000	28/05	MT
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024	21/05	PR
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase	20/05	PR
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally	07/05	PR
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024	07/05	CI
IceCure Medical : Company Presentation	23/04	PU
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	16/04	AQ
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	16/04	MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	15/04	CI
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes	03/04	AQ
Transcript : IceCure Medical Ltd, 2023 Earnings Call, Apr 03, 2024	03/04
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03/04	CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology	03/04	MT
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes	02/04	PR
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes	02/04	CI
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024	27/03	PR
Alliance Global Partners Adjusts IceCure Medical Price Target to $2.90 From $1.90, Maintains Buy Rating	20/03	MT
IceCure Medical Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	20/03	AQ
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy	19/03	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News IceCure Medical Ltd

Equities

ICCM

IL0011224156

Summary

Filters